New FDA Approvals
New FDA Approvals
These drugs have received final approval from the Food and Drug Administration:
- Antidepressant Effexor XR (venlafaxine HCl) Extended-Release Capsules by Wyeth-Ayerst. The FDA has approved a new label change for venlafaxine extended-release capsules for use as a long-term treatment for generalized anxiety disorder (GAD). This marks the first antidepressant indicated for long-term therapy for GAD.
- Antihistamine Astelin (azelastine HCl) Nasal Spray by Wallace Laboratories. The FDA has approved its use treatment of seasonal allergic rhinitis in pediatric patients as young as 5 at a dosage of one spray per nostril twice a day (0.55 mg/day). Azelastine nasal spray previously had approval for treatment of patients 12 and older.
- Asthma agent Advair Diskus (fluticasone propionate and salmeterol inhalation powder) by Glaxo Wellcome. This dual-action medication is the first to be approved for use in the United States for the long-term twice-daily, maintenance treatment
of asthma in patients 12 and older. The new inhaler contains an inhaled corticosteroid (fluticasone propionate) to reduce inflammation, and an inhaled long-acting bronchodilator (salmeterol) to help prevent bronchoconstriction. Together, inflammation and bronchoconstriction cause the symptoms of asthma. The combination inhaler is not indicated
for the relief of acute bronchospasm.
- Sulfasalazine delayed-release tablet (Azulfadine EN-tab) by Pharmacia. This sulfasalazine is now approved for the treatment of pediatric patients with polyarticular course juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. MGI Pharma will co-promote the product.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.